irinotecan has been researched along with Nausea in 88 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (12.50) | 18.2507 |
| 2000's | 45 (51.14) | 29.6817 |
| 2010's | 23 (26.14) | 24.3611 |
| 2020's | 9 (10.23) | 2.80 |
| Authors | Studies |
|---|---|
| Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C | 1 |
| Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H | 1 |
| Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S | 1 |
| Chen, Z; Jiang, Y; Song, B | 1 |
| Hoogeman, M; Loi, M; Magallon-Baro, A; Nuyttens, JJ; Suker, M; Van Eijck, C | 1 |
| Acharya, A; Amin, M; Copsey, ML; Gao, F; Jin, RU; Lim, KH; Lockhart, AC; Morton, AE; Navo, KA; Park, H; Pedersen, KS; Rigden, C; Suresh, R; Tan, BR; Trikalinos, NA; Wang-Gillam, A | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Aldaz Pastor, A; Garcia-Del-Barrio, MA; Martin-Algarra, S | 1 |
| Fan, Z; Liu, B; Lu, T; Tong, H | 1 |
| Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L | 1 |
| Liu, JZ; Liu, WW; Liu, ZL; Wang, B | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D | 1 |
| Bayraktar, S; Broome, P; de Queiroz Marques Junior, E; Leslie, M; Nowacki, M; Rocha-Lima, CM; Susnerwala, S; Weissman, C | 1 |
| Goto, K; Matsumoto, S; Morise, M; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K | 1 |
| Eto, K; Fukushima, H; Furuhata, T; Isobe, H; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Kudo, M; Masuko, H; Minami, S; Miyagishima, T; Nakajima, J; Nakamura, M; Oba, K; Ohsaki, Y; Okita, K; Sasaki, K; Shibuya, H; Takahashi, Y; Tateyama, M; Yokoyama, R; Yuki, S | 1 |
| Inoue, A; Ishimoto, O; Maemondo, M; Nukiwa, T; Sugawara, S | 1 |
| Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ | 1 |
| Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N | 1 |
| Bueno, R; Choi, N; Cleary, JM; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Gaissert, HA; Jaklitsch, MT; Kulke, MH; Lynch, TP; Mamon, HJ; Mentzer, SJ; Meyerhardt, JA; Swanson, RS; Szymonifka, J; Wain, J | 1 |
| Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M | 1 |
| Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, L | 1 |
| Fukuoka, M; Komiya, T; Kurata, T; Miyazaki, M; Nakagawa, K; Takeda, K; Tamura, K; Tsurutani, J; Yamamoto, N | 1 |
| Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM | 1 |
| Bosnjak, SM; Hesketh, PJ; Nikolic, V; Rapoport, B | 1 |
| Daimon, T; Furuse, K; Kawahara, M; Mio, T; Okishio, K; Yanagihara, K; Yoshioka, H | 1 |
| Fujiwara, H; Harada, T; Itamochi, H; Kigawa, J; Machida, S; Oishi, T; Sato, S; Shimada, M; Suzuki, M; Takei, Y | 1 |
| Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L | 1 |
| Chaudhary, UB; Gudena, V; Keane, T; Verma, N | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE | 1 |
| Akasu, T; Fujita, S; Hosokawa, A; Matsumura, Y; Moriya, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y | 1 |
| Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC | 1 |
| Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT | 1 |
| Bittorf, B; Brueckl, V; Brueckl, WM; Hahn, EG; Hegewald, J; Hohenberger, W; Jüngert, B; Männlein, G; Mühldorfer, S; Schirner, I; Stickel, F; Wein, A | 1 |
| Shirao, K; Ura, T | 1 |
| Eguchi, K; Kobayashi, K; Matsumoto, T; Morita, S; Ohashi, Y; Sakamoto, J; Shibuya, M; Yamaji, Y | 1 |
| Ariyoshi, Y; Fukuoka, M; Hoso, T; Katakami, N; Kawahara, M; Kudoh, S; Matsui, K; Nakagawa, K; Nakano, T; Negoro, SI; Saito, H; Senba, H; Sugiura, T; Takada, Y; Yamamoto, N | 1 |
| Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G | 1 |
| Bereder, JM; Bernardini, D; Cals, L; Deplanque, G; Favre, R; François, E; Herait, P; Juin, P; Laadem, A; Merad, L; Rixe, O | 1 |
| Holcombe, RF; Kong, KM; Wimmer, D | 1 |
| Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J | 1 |
| Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C | 1 |
| Jung, SH; Kirsh, KL; Loehrer, P; Nagy, C; Navari, RM; Passik, SD; Vinson, J | 1 |
| Fushiki, H | 1 |
| Assadourian, S; de Jong, FA; de Jonge, MJ; Dumez, H; Eskens, FA; Lefebvre, P; Sanderink, GJ; Selleslach, J; Soepenberg, O; Sparreboom, A; Ter Steeg, J; Thomas, J; van Oosterom, AT; van Schaik, RH; Verweij, J | 1 |
| Bauer, I; Freund, M; Köhne, CH; Schuff-Werner, P; Seule, M; Steiner, B; Steiner, M | 1 |
| Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP | 1 |
| Hanyu, F; Harada, N; Hayashi, T; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Akasaka, Y; Hata, Y; Honda, S; Ito, T; Matsuoka, S; Nakajima, N; Ohmori, K; Sano, F; Yokoyama, R | 1 |
| Fung, A; Viale, PH; Zitella, L | 1 |
| Fukunaga, H; Ikeda, M; Ikenaga, M; Monden, M; Ohue, M; Sekimoto, M; Seshimo, I; Takayama, O; Yamamoto, H; Yasui, M | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L | 1 |
| Azrak, RG; Badmaev, V; Creaven, PJ; Fakih, MG; Lawrence, D; Pendyala, L; Prey, JD; Reid, ME; Rustum, YM; Smith, PF | 1 |
| Fujita, A; Hayakawa, T; Hirohata, T; Inotsume, N; Konaka, M; Makino, A; Sato, H; Sato, M; Sekine, K; Totsu, S; Wada, Y | 1 |
| Iwamoto, S; Yoshioka, K | 1 |
| Horai, T; Kasahara, K; Nishio, M; Ohyanagi, F; Shibata, K; Shirosaki, H; Taguchi, F; Takeda, Y | 1 |
| Asaka, M; Komatsu, Y; Miyagishima, T; Yuki, S | 1 |
| Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S | 1 |
| Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D | 1 |
| Amado, RG; Berlin, J; Hecht, JR; Malik, I; Meropol, NJ; Navale, L; Patnaik, A; Tchekmedyian, S; Venook, A | 1 |
| He, YJ; Jiang, WQ; Li, YH; Luo, HY; Shi, YX; Wang, F; Xu, RH; Zhang, L | 1 |
| Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH | 1 |
| Boige, V; Cohen, M; Delbaldo, C; Faivre, S; Namouni, F; Pautier, P; Peck, R; Raymond, E; Soria, JC | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Gandia, D; Gouyette, A; Hérait, P | 1 |
| Ariyoshi, Y; Furue, H; Kimura, I; Masaoka, T; Ogawa, M; Oguro, M; Ohno, R; Saito, H; Sakai, Y; Yoshida, Y | 1 |
| Ishida, T; Izuo, M; Nakao, I; Ogawa, M; Oguro, M; Ohkawa, T; Taguchi, T; Tominaga, T; Yoshida, M; Yoshida, Y | 1 |
| Futatsuki, K; Kambe, M; Nakao, I; Ogawa, N; Sakata, Y; Shimada, Y; Taguchi, T; Wakui, A; Yoshino, M | 1 |
| Ariyoshi, Y; Hotta, T; Kobayashi, T; Ogura, M; Ohashi, Y; Ohnishi, K; Ohno, R; Saito, H; Shirakawa, S; Takeyama, K; Tobinai, K | 1 |
| Bailey, H; Durivage, HJ; Gelder, M; Irvin, WP; Potkul, RK; Price, FV; Rosenbluth, R | 1 |
| Balis, FM; Blaney, SM; Cole, DE; Godwin, K; Kuttesch, N; McCully, C; Murry, DJ; Takimoto, C | 1 |
| Abe, S; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Saijo, N; Suzuki, S; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Depisch, D; Haider, K; Hejna, M; Kornek, GV; Kwasny, W; Raderer, M; Scheithauer, W; Valencak, J; Weinländer, G | 1 |
| Cox, JV; DeVore, RF; Elfring, GL; Geyer, CE; Hainsworth, JD; Macdonald, JS; Miller, LL; Mohrland, JS; Pazdur, R; Rivkin, SE; Rothenberg, ML; Sandbach, J; Von Hoff, DD; Wolf, DL | 1 |
| Allegra, CJ; Arbuck, SG; Band, RA; Berger, NA; Berger, SJ; Chen, AP; Cottrell, J; Flemming, D; Gosky, DM; Grem, JL; Guemei, A; Hamilton, JM; Harold, N; Hehman, H; Hirota, H; Ismail, AS; Llorens, V; Monahan, BP; Morrison, G; Quinn, M; Shapiro, JD; Takimoto, CH; Wright, J | 1 |
| Kelsen, DP; Kemeny, NE; O'Reilly, EM; Raeburn, L; Saltz, LB; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Stuart, KE | 1 |
| Delioukina, ML; Hecht, JR; Parson, M; Prager, D; Rosen, LS; Rosen, P | 1 |
| Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hammett, E; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL | 1 |
| Fukuoka, M; Hasegawa, K; Kimura, M; Kurita, Y; Kuriyama, T; Motomiya, M; Nakabayashi, T; Negoro, S; Niitani, H; Suzuki, A | 1 |
9 review(s) available for irinotecan and Nausea
| Article | Year |
|---|---|
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Fluorouracil; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2018 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; Hematologic Diseases; Humans; Incidence; Irinotecan; Lung Neoplasms; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vomiting | 2018 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Logistic Models; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Stomatitis; Survival Analysis; Treatment Outcome | 2011 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Nausea; Stomatitis; Thrombocytopenia; Vomiting | 2003 |
[Kampo therapy for side effects of gynecologic carcinomatous chemotherapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cytokines; Drugs, Chinese Herbal; Female; Genital Neoplasms, Female; Hematopoiesis; Humans; Irinotecan; Leukopenia; Lymphocyte Activation; Mice; Nausea; Peripheral Nervous System Diseases; Phytotherapy; Thrombocytopenia; Vomiting; Weight Loss | 2004 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cause of Death; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Costs; Drug Hypersensitivity; Drug Industry; Female; Fluorouracil; Humans; Irinotecan; Male; Medical Assistance; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Patient Education as Topic; Treatment Outcome; United States; Vomiting | 2005 |
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting | 2007 |
58 trial(s) available for irinotecan and Nausea
| Article | Year |
|---|---|
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Data Analysis; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Nausea; Organs at Risk; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiation Dosage; Radiosurgery; Time Factors | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Oxaliplatin; Peripheral Nervous System Diseases; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2020 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Dietary Supplements; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Pilot Projects; Prospective Studies; Protective Agents; Silymarin; Treatment Outcome; Young Adult | 2021 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Treatment Outcome; Vomiting; Young Adult | 2017 |
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome | 2013 |
A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Gastrins; Humans; Infusions, Intravenous; Injections, Intramuscular; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Vomiting | 2014 |
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Female; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quality of Life; Quinuclidines; Serotonin Antagonists; Treatment Outcome | 2015 |
Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Feasibility Studies; Febrile Neutropenia; Female; Humans; Hypokalemia; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2015 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Hedgehog Proteins; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome; Veratrum Alkaloids; Vomiting | 2016 |
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Chemoradiotherapy; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Cyclooxygenase 2 Inhibitors; Deglutition Disorders; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging | 2016 |
Population-based phase I trial of irinotecan and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors | 2008 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Nausea; Proctitis; Rectal Neoplasms; Remission Induction; Vomiting | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Salvage Therapy; Survival Rate; Vomiting; Young Adult | 2009 |
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome | 2010 |
A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Topics: Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2012 |
Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Genetic Variation; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds | 2012 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome | 2012 |
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Vomiting | 2002 |
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Hypotension; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2002 |
Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Linear Models; Lung Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Vindesine; Vomiting, Anticipatory | 2003 |
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Survival Analysis; Taxoids; Vomiting | 2004 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronides; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Patient Selection; Quinazolines; Thiophenes; Vomiting | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2004 |
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Treatment Outcome | 2004 |
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzodiazepines; Camptothecin; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mood Disorders; Nausea; Neoplasms; Olanzapine; Organoplatinum Compounds; Time Factors; Treatment Outcome; Vomiting | 2004 |
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Capsules; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; Dietary Fats; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Survival Rate; Tegafur; Uracil; Vomiting, Anticipatory | 2005 |
Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Granisetron; Humans; Irinotecan; Male; Middle Aged; Nausea; Pilot Projects; Vomiting | 2005 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2005 |
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Selenomethionine; Treatment Outcome | 2006 |
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Platinum; Survival Rate | 2006 |
[Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capsules; Diarrhea; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Nausea; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Remission Induction; Tegafur | 2006 |
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Skin Diseases; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Epothilones; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Paresthesia; Vomiting | 2008 |
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Treatment Outcome; Vomiting | 1995 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Irinotecan; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia | 1994 |
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Organ Specificity; Vomiting | 1993 |
Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Vomiting | 1996 |
A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Patient Satisfaction; Pilot Projects; Platinum Compounds; Remission Induction; Safety; Uterine Cervical Neoplasms; Vomiting | 1998 |
Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Nausea; Recombinant Proteins; Reproducibility of Results; Vomiting | 1997 |
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Vomiting | 1999 |
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Vomiting | 2000 |
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Diarrhea; Fatigue; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Prognosis; Treatment Outcome; Vomiting | 2001 |
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Pilot Projects | 2002 |
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Deoxycytidine; Drug Administration Schedule; Esophagitis; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Neutropenia; Recurrence; Stomatitis; Treatment Outcome; Vomiting | 2002 |
[A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Vomiting | 1991 |
21 other study(ies) available for irinotecan and Nausea
| Article | Year |
|---|---|
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; COVID-19; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Oxaliplatin; Palonosetron; Pandemics; Prospective Studies; Pyridines; Vomiting | 2021 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Nausea; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; Camptothecin; Diarrhea; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Thrombocytopenia; Vomiting | 2022 |
Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis.
Topics: Abdominal Pain; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Exanthema; Female; Humans; Hyperglycemia; Irinotecan; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms; Vomiting | 2022 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nausea; Neoplasm Metastasis; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Vomiting | 2021 |
Reality of the emetogenic level of irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Emetics; Female; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Outpatients; Quality of Life; Retrospective Studies; Severity of Illness Index; Vomiting | 2018 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Records; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Severity of Illness Index; Small Cell Lung Carcinoma; Treatment Outcome; Vomiting | 2014 |
Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dexamethasone; Drug Therapy, Combination; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Nausea; Prospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vomiting, Anticipatory | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Middle Aged; Nausea; Pilot Projects; Rectal Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome; Vomiting, Anticipatory | 2003 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Vomiting | 2003 |
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Heterozygote; Humans; Irinotecan; Mutation; Nausea; Sigmoid Neoplasms; Vomiting | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Rectal Neoplasms | 2005 |
[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cisplatin; Female; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Oxazines; Retrospective Studies; Vomiting, Anticipatory | 2006 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Tegafur; Uracil | 2006 |
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2007 |
Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Irinotecan; Macaca mulatta; Male; Nausea; Vomiting | 1998 |